NCT02550678 - A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions

Basal Cell Nevus SyndromeSkin NeoplasmNodular Basal Cell Carcinoma of Skin

Interventions

BIOLOGICAL

ASN-002

ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.

DRUG

5-FU

5-FU is chemotherapeutic agent used to treat various cancers.

Trial Locations (4)

2217

St George Dermatology and Skin Cancer Centre, Kogarah

3002

Sinclair Dermatology, Melbourne

4000

Siller Medical T/A Central Brisbane Dermatology, Brisbane

4102

Veracity Clinical Research, Brisbane